Breast Neoplasm
Conditions
Keywords
Breast cancer
Brief summary
The two drugs used to treat metastatic breast cancer in this study may perform better when used together than when used separately. The use of another drug that prevents the most common side effect of the two-drug combination permits the delivery of both agents at closer to the full dose for either when used alone. We hypothesize that the two-drug combination used with G-CSF support will be more effective and less toxic than other standard regimens for the treatment of metastatic breast cancer.
Detailed description
Preclinical data suggest that there may be synergy between vinorelbine and paclitaxel when the two drugs are used in combination such that the effect of the two together may be better than either alone. Clinical data suggest that the use of concurrent G-CSF with paclitaxel and vinorelbine permits the delivery of both agents at approximately 70% of the full dose for either, used alone without G-CSF support, with myelosuppression as the usual dose-limiting toxicity and no unusual or unexpected complications. Encouragingly, 8/20 (40%) patients had objective responses, with three complete remissions (15%) in this program of third-line therapy. Therefore, we now propose to combine docetaxel at about 70% of full dose with vinorelbine at 27.5 mg/m2, the phase II dose defined in the previous trial. Docetaxel will be given on day 1 followed by vinorelbine on days 8 and 15, with G-CSF to be administered on all days except that of docetaxel administration. The cycle is to be repeated every three weeks.
Interventions
DRUGDocetaxel
60 mg/m2, IV, day 1 of each 21 day cycle
DRUGVinorelbine
27.5 mg/m2, IV, days 8 & 15 of each 21 day cycle
DRUGFilgrastim
5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
Sponsors
Aventis Pharmaceuticals
University of Washington
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have stage IV, microscopically-confirmed carcinoma of the breast with histologic slides and/or blocks available for review. * Patients must have relapse or progression while receiving, or within 12 months of having received, anthracycline-containing (doxorubicin or mitoxantrone) regimen as either adjuvant treatment or therapy for advanced breast cancer. Prior Taxol by 3- or 24-hour infusion is permitted. Patients who have received a maximum dose of anthracycline (greater than 450 mg/m2) are also eligible. * Patients must have measurable (bidimensionally) or evaluable disease. * Patients must be 18 or more years of age. * Patients must have a Karnofsky Performance Status greater than or equal to 70% at screen and on the first day of treatment. * Patients must have a life expectancy of more than 16 weeks. * Prior irradiation is permitted, provided that prior irradiation does not exceed 25% of the estimated bone marrow volume and provided that measurable/evaluable disease exists outside the radiation field OR there must be histologic proof of progressive disease within a radiation field. * Informed consent must be obtained prior to registration. * Patients must be more than 2 weeks from prior surgery; more than 3 weeks from radiation therapy to the pelvis, spine or long bones; more than 3 weeks from prior chemotherapy (more than 6 weeks for mitomycin C or nitrosureas), or more than 2 weeks from prior hormonal therapy. * All patients must have appropriate central venous access.
Exclusion criteria
Patients are excludes if their: * Granulocyte count is less than 1,500/mm3. * Platelet count is less than 100,000/mm3. * Hemoglobin is less than 9 gm/dl. * Creatinine is greater than 2.0 mg/dl. * Total bilirubin is greater than ULN (institutional upper limit of normal).. * SGOT (AST) and/or SGPT (ALT) is greater than 1.5 x ULN concomitant with alkaline phosphatase greater than 2.5 x ULN. Patients are excluded if they are: * In visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung metastases. * Medically unstable. * Pregnant or lactating. Patients are excluded if they have: * Uncontrolled CNS disease. * Pre-existing clinically significant peripheral neuropathy except for abnormalities due to cancer. * Psychological, familial, sociological or geographical conditions which do not permit weekly medical follow-up and compliance with the study protocol. * Prior therapy with Navelbine. * Sensitivity to E. Coli-derived proteins.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response to treatment | Until disease progression |
| Toxicity of treatment | Until completion of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Time to progression | Until disease progression occurs |
| Over all survival | Until study is closed |
Countries
United States
Outcome results
None listed